-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

Truist Downgrades Fate Therapeutics to Hold From Buy, Adjusts Price Target to $7 From $46

Truist Downgrades Fate Therapeutics to Hold From Buy, Adjusts Price Target to $7 From $46

MT Newswires · 01/06/2023 03:00